JAGX - Jaguar Health, Inc. Stock Analysis

Stock Taper

SCREENER COMPARE ANY 2 STOCKS

JAGX

JAGUAR HEALTH, INC.

NASDAQ

$0.81

▼ DOWN 6.37% (-0.06)

KEY STATISTICS

Market Cap$53.97 K

52w High$85.40

52w Low$0.72

Dividend Yield—

Frequency—

P/E-0.02

Volume156.25K

Shares Out.66.64K

COMPANY

LEADERSHIP

CHIEF EXECUTIVE

Lisa A. Conte

ABOUT

SECTOR

Healthcare

WENT PUBLIC

May 12, 2015

METHOD OF GOING PUBLIC

Reverse Merger

FULL TIME EMPLOYEES

PRICE TARGET

Target High$3.21

Target Low$3.21

Target Median$3.21

Target Consensus$3.21

UPCOMING EARNINGS

DateNov 12, 2026

DayThursday

Rev. Est.$4.85M

NOV

THU

SPLIT RECORD

DATE	TYPE	RATIO
2026-04-30	Reverse	1:35
2025-03-24	Reverse	1:25
2024-05-23	Reverse	1:60
2023-01-23	Reverse	1:75
2021-09-08	Reverse	1:3
2019-06-07	Reverse	1:70
2018-06-01	Reverse	1:15

PRICE

$0.81 ▼ DOWN 6.37% (−$0.06)

OVERLAYS

About Jaguar Health, Inc.

https://jaguar.health ↗

Jaguar Health, Inc. develops prescription medicines for gastrointestinal distress in humans and animals, including Mytesi, Crofelemer, and Canalevia, targeting conditions like diarrhea in HIV, cancer, infants, and dogs.

INDUSTRY

Biotechnology

A PRODUCT JAGUAR HEALTH, INC. IS KNOWN FOR

Mytesi (crofelemer)

Mytesi, an FDA-approved prescription for non-infectious diarrhea in adults with HIV/AIDS, is Jaguar Health's key product, generating significant revenue and recently expanded through a January 2026 partnership to enhance U.S. marketing and manufac...